What does Seres Therapeutics, Inc. do?
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream…
What is Seres Therapeutics, Inc.'s P/E and P/B ratio?
Seres Therapeutics, Inc. has a P/E ratio of -0.9 and a P/B ratio of 0.62.
What is Seres Therapeutics, Inc.'s debt-to-equity ratio?
Seres Therapeutics, Inc. has a debt-to-equity ratio of 1.64.
How much does Seres Therapeutics, Inc. owe compared with what it owns?
Seres Therapeutics, Inc. owes $0.66 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Seres Therapeutics, Inc.'s Positivity rank?
Seres Therapeutics, Inc. is ranked #1,897 of 6,774 companies globally and #490 of 4,000 in United States on PositoAI, with a Positivity Score of 22,153.
Does Seres Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Seres Therapeutics, Inc..
Where can I read the latest news about Seres Therapeutics, Inc.?
Recent headlines about Seres Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Seres Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Seres Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.